A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

European Respiratory Journal

Volumn 20, Issue 3, 2002, Pages 658-664

  Hodson, M E ^a   Gallagher, C G ^a   Govan, J R W ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Colistin; Cystic fibrosis; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

COLISTIN; DORNASE ALFA; TOBRAMYCIN;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CELL DENSITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DETERIORATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; PHARYNGITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; CHILD; CHRONIC DISEASE; COLISTIN; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 0036736583     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00248102     Document Type: Article

References (25)

1. Cystic fibrosis and endobronchial Pseudomonas infection
2. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients
3. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia
4. The changing epidemiology of cystic fibrosis
5. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
6. Prediction of mortality in patients with cystic fibrosis
7. Respiratory management
8. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
9. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
10. Use of aerosolized antibiotics in patients with cystic fibrosis
11. Inhalation of antibiotics in cystic fibrosis
12. Guidelines for antimicrobial prescribing in cystic fibrosis
13. Nebulised antibiotics for adults with cystic fibrosis
14. Inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
16. Long-term efficacy and safety of inhaled tobramycin (TOBI) in patients with cystic fibrosis
17. Changes in the normal maximal expiratory flow-volume curve with growing and aging
18. Measurement of health status: Ascertaining minimal clinically important difference
19. Standardization of spirometry, 1994 update
20. Microbiology of sputum from patients at cystic fibrosis centers in the United States
21. Efficacy of aerosolised tobramycin in patients with cystic fibrosis